DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

Arvee Laboratories (India) Limited — Corrigendum

NSE 3 hrs ago·4 Aug 2026, 8:42 am

Arvee Laboratories I

Arvee Laboratories (India) Limited has issued a corrigendum, which is a correction to a previously announced statement. This indicates that the company is revising or updating some information it had provided earlier. The corrigendum could be related to various aspects such as financial reports, announcements, or other disclosures made by the company. It is essential for investors to be aware of such corrections as they may impact their understanding of the company's performance or prospects. Investors should watch for further updates from the company to understand the implications of the corrigendum and how it may affect their investment decisions.